NM_000249.4(MLH1):c.59C>G (p.Ala20Gly) AND Hereditary cancer-predisposing syndrome

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Dec 24, 2015
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV004522903.1

Allele description [Variation Report for NM_000249.4(MLH1):c.59C>G (p.Ala20Gly)]

NM_000249.4(MLH1):c.59C>G (p.Ala20Gly)

Gene:

MLH1:mutL homolog 1 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

3p22.2

Genomic location:

Preferred name:

NM_000249.4(MLH1):c.59C>G (p.Ala20Gly)

HGVS:

NC_000003.12:g.36993606C>G
NG_007109.2:g.5257C>G
NG_008418.1:g.4699G>C
NG_099042.2:g.135C>G
NM_000249.4:c.59C>GMANE SELECT
NM_001167617.3:c.-458C>G
NM_001167618.3:c.-887C>G
NM_001167619.3:c.-800C>G
NM_001258271.2:c.59C>G
NM_001258273.2:c.-574C>G
NM_001258274.3:c.-1037C>G
NM_001354615.2:c.-568C>G
NM_001354616.2:c.-568C>G
NM_001354617.2:c.-660C>G
NM_001354618.2:c.-892C>G
NM_001354619.2:c.-1016C>G
NM_001354620.2:c.-226C>G
NM_001354621.2:c.-985C>G
NM_001354622.2:c.-1098C>G
NM_001354623.2:c.-1007C>G
NM_001354624.2:c.-768C>G
NM_001354625.2:c.-666C>G
NM_001354626.2:c.-763C>G
NM_001354627.2:c.-995C>G
NM_001354628.2:c.59C>G
NM_001354629.2:c.59C>G
NM_001354630.2:c.59C>G
NP_000240.1:p.Ala20Gly
NP_000240.1:p.Ala20Gly
NP_001245200.1:p.Ala20Gly
NP_001341557.1:p.Ala20Gly
NP_001341558.1:p.Ala20Gly
NP_001341559.1:p.Ala20Gly
LRG_216t1:c.59C>G
LRG_216:g.5257C>G
LRG_216p1:p.Ala20Gly
NC_000003.11:g.37035097C>G
NM_000249.3:c.59C>G

Protein change:

A20G

Molecular consequence:

NM_001167617.3:c.-458C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001167618.3:c.-887C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001167619.3:c.-800C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001258273.2:c.-574C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001258274.3:c.-1037C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354615.2:c.-568C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354616.2:c.-568C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354617.2:c.-660C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354618.2:c.-892C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354619.2:c.-1016C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354620.2:c.-226C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354621.2:c.-985C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354622.2:c.-1098C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354623.2:c.-1007C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354624.2:c.-768C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354625.2:c.-666C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354626.2:c.-763C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_001354627.2:c.-995C>G - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
NM_000249.4:c.59C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001258271.2:c.59C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001354628.2:c.59C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001354629.2:c.59C>G - missense variant - [Sequence Ontology: SO:0001583]
NM_001354630.2:c.59C>G - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Hereditary cancer-predisposing syndrome
Synonyms:: Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV005033198	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Dec 24, 2015)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV005033198

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Dec 24, 2015)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV005033198.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The p.A20G variant (also known as c.59C>G), located in coding exon 1 of the MLH1 gene, results from a C to G substitution at nucleotide position 59. The alanine at codon 20 is replaced by glycine, an amino acid with similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.001% (greater than 115000 alleles tested) in our clinical cohort. This amino acid position is highly conserved in available vertebrate species. This alteration is predicted to be probably damaging and deleterious by PolyPhen and SIFT in silico analyses, respectively. In addition, this alteration is predicted to be deleterious by MAPP-MMR in silico analysis (Chao E et al. Hum Mutat. 2008 Jun; 29(6):852-60). Since supporting evidence is limited at this time, the clinical significance of p.A20G remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: May 7, 2024

ClinVar

Relating variation to medicine